Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade

Christopher P Evans, Fred Elfman, Sareh Parangi, Marion Conn, Gerald Cunha, Marc A. Shuman

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Binding of the serine protease urokinase (u-PA) to its receptor on tumor cell surfaces facilitates proteolysis and tumor invasion. We undertook this study to determine whether the role of u-PA in prostate cancer induced angiogenesis and secondary tumor growth by developing a homologous, immunocompetent in vivo model in which the tumors cells secrete an inhibitor of the murine u-PA receptor. A mutant recombinant murine u-PA that retains receptor binding but not proteolytic activity was made by PCR mutagenesis. Mutant u-PA and a reporter gene pRK luciferase were transfected and stably expressed in the highly metastatic rat Dunning MAT-LyLu prostate cancer cell line. Several clones expressing mutant u-PA and luciferase were identified by Western blotting, plasminogen zymography, and reverse transcription-PCR. One of these clones, 5C4, was injected s.c. into Copenhagen rats. Compared to animals injected with clones expressing pRK luciferase alone, tumors in animals injected with 5C4 cells were significantly smaller. Moreover, there were fewer lung micrometastases in the 5C4 animals. Primary tumor angiogenesis was measured by microvessel quantification of tissue stained with antibodies against von Willebrand factor. Mean microvessel density in 5C4 tumors was 4.3-fold lower than that in animals with tumors derived from the control tumor cell line (P < 0.0001). Significant inhibition of tumor growth was also observed for two additional MAT-LyLu cell lines expressing mutant u-PA. These findings suggest that cell surface u-PA contributes to prostate cancer growth by enhancing angiogenesis.

Original languageEnglish (US)
Pages (from-to)3594-3599
Number of pages6
JournalCancer Research
Volume57
Issue number16
StatePublished - Aug 15 1997

Fingerprint

Urokinase Plasminogen Activator Receptors
Prostatic Neoplasms
Growth
Neoplasms
Luciferases
Clone Cells
Microvessels
Cell Line
Polymerase Chain Reaction
Neoplasm Micrometastasis
Plasminogen
Urokinase-Type Plasminogen Activator
von Willebrand Factor
Serine Proteases
Tumor Cell Line
Reporter Genes
Mutagenesis
Proteolysis
Reverse Transcription
Western Blotting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evans, C. P., Elfman, F., Parangi, S., Conn, M., Cunha, G., & Shuman, M. A. (1997). Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Research, 57(16), 3594-3599.

Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. / Evans, Christopher P; Elfman, Fred; Parangi, Sareh; Conn, Marion; Cunha, Gerald; Shuman, Marc A.

In: Cancer Research, Vol. 57, No. 16, 15.08.1997, p. 3594-3599.

Research output: Contribution to journalArticle

Evans, CP, Elfman, F, Parangi, S, Conn, M, Cunha, G & Shuman, MA 1997, 'Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade', Cancer Research, vol. 57, no. 16, pp. 3594-3599.
Evans, Christopher P ; Elfman, Fred ; Parangi, Sareh ; Conn, Marion ; Cunha, Gerald ; Shuman, Marc A. / Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. In: Cancer Research. 1997 ; Vol. 57, No. 16. pp. 3594-3599.
@article{c1d57c2c1f304cb9af01c2357dbd5ede,
title = "Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade",
abstract = "Binding of the serine protease urokinase (u-PA) to its receptor on tumor cell surfaces facilitates proteolysis and tumor invasion. We undertook this study to determine whether the role of u-PA in prostate cancer induced angiogenesis and secondary tumor growth by developing a homologous, immunocompetent in vivo model in which the tumors cells secrete an inhibitor of the murine u-PA receptor. A mutant recombinant murine u-PA that retains receptor binding but not proteolytic activity was made by PCR mutagenesis. Mutant u-PA and a reporter gene pRK luciferase were transfected and stably expressed in the highly metastatic rat Dunning MAT-LyLu prostate cancer cell line. Several clones expressing mutant u-PA and luciferase were identified by Western blotting, plasminogen zymography, and reverse transcription-PCR. One of these clones, 5C4, was injected s.c. into Copenhagen rats. Compared to animals injected with clones expressing pRK luciferase alone, tumors in animals injected with 5C4 cells were significantly smaller. Moreover, there were fewer lung micrometastases in the 5C4 animals. Primary tumor angiogenesis was measured by microvessel quantification of tissue stained with antibodies against von Willebrand factor. Mean microvessel density in 5C4 tumors was 4.3-fold lower than that in animals with tumors derived from the control tumor cell line (P < 0.0001). Significant inhibition of tumor growth was also observed for two additional MAT-LyLu cell lines expressing mutant u-PA. These findings suggest that cell surface u-PA contributes to prostate cancer growth by enhancing angiogenesis.",
author = "Evans, {Christopher P} and Fred Elfman and Sareh Parangi and Marion Conn and Gerald Cunha and Shuman, {Marc A.}",
year = "1997",
month = "8",
day = "15",
language = "English (US)",
volume = "57",
pages = "3594--3599",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade

AU - Evans, Christopher P

AU - Elfman, Fred

AU - Parangi, Sareh

AU - Conn, Marion

AU - Cunha, Gerald

AU - Shuman, Marc A.

PY - 1997/8/15

Y1 - 1997/8/15

N2 - Binding of the serine protease urokinase (u-PA) to its receptor on tumor cell surfaces facilitates proteolysis and tumor invasion. We undertook this study to determine whether the role of u-PA in prostate cancer induced angiogenesis and secondary tumor growth by developing a homologous, immunocompetent in vivo model in which the tumors cells secrete an inhibitor of the murine u-PA receptor. A mutant recombinant murine u-PA that retains receptor binding but not proteolytic activity was made by PCR mutagenesis. Mutant u-PA and a reporter gene pRK luciferase were transfected and stably expressed in the highly metastatic rat Dunning MAT-LyLu prostate cancer cell line. Several clones expressing mutant u-PA and luciferase were identified by Western blotting, plasminogen zymography, and reverse transcription-PCR. One of these clones, 5C4, was injected s.c. into Copenhagen rats. Compared to animals injected with clones expressing pRK luciferase alone, tumors in animals injected with 5C4 cells were significantly smaller. Moreover, there were fewer lung micrometastases in the 5C4 animals. Primary tumor angiogenesis was measured by microvessel quantification of tissue stained with antibodies against von Willebrand factor. Mean microvessel density in 5C4 tumors was 4.3-fold lower than that in animals with tumors derived from the control tumor cell line (P < 0.0001). Significant inhibition of tumor growth was also observed for two additional MAT-LyLu cell lines expressing mutant u-PA. These findings suggest that cell surface u-PA contributes to prostate cancer growth by enhancing angiogenesis.

AB - Binding of the serine protease urokinase (u-PA) to its receptor on tumor cell surfaces facilitates proteolysis and tumor invasion. We undertook this study to determine whether the role of u-PA in prostate cancer induced angiogenesis and secondary tumor growth by developing a homologous, immunocompetent in vivo model in which the tumors cells secrete an inhibitor of the murine u-PA receptor. A mutant recombinant murine u-PA that retains receptor binding but not proteolytic activity was made by PCR mutagenesis. Mutant u-PA and a reporter gene pRK luciferase were transfected and stably expressed in the highly metastatic rat Dunning MAT-LyLu prostate cancer cell line. Several clones expressing mutant u-PA and luciferase were identified by Western blotting, plasminogen zymography, and reverse transcription-PCR. One of these clones, 5C4, was injected s.c. into Copenhagen rats. Compared to animals injected with clones expressing pRK luciferase alone, tumors in animals injected with 5C4 cells were significantly smaller. Moreover, there were fewer lung micrometastases in the 5C4 animals. Primary tumor angiogenesis was measured by microvessel quantification of tissue stained with antibodies against von Willebrand factor. Mean microvessel density in 5C4 tumors was 4.3-fold lower than that in animals with tumors derived from the control tumor cell line (P < 0.0001). Significant inhibition of tumor growth was also observed for two additional MAT-LyLu cell lines expressing mutant u-PA. These findings suggest that cell surface u-PA contributes to prostate cancer growth by enhancing angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0030812212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030812212&partnerID=8YFLogxK

M3 - Article

C2 - 9270033

AN - SCOPUS:0030812212

VL - 57

SP - 3594

EP - 3599

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -